🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Sunshine Lake Pharma clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Sunshine Lake Pharma as lead sponsor. Synced 26 Sep 2026
15Current trials
11Recruiting now
12Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Sunshine Lake Pharma is the lead sponsor of 15 current clinical trials in our China register. 11 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Clifutinib, HEC585 and Pirfenidone. The most-studied condition is Esophageal Cancer.

ClinicalTrials.gov trials by status

  • Recruiting1173%
  • Not yet open320%
  • Active, closed17%

Trials by phase

  • Phase 1747%
  • Phase 3320%
  • Phase 2213%
  • Phase 1/2213%
  • Phase 2/317%
01

Clinical trials sponsored by Sunshine Lake Pharma

15 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
NCT07082842 · ClinicalTrials.gov ↗ · Idiopathic Pulmonary Fibrosis (IPF)
Phase 3 Recruiting 2025-10 China
Single-ascending Dose Study of HEC-151 Injection
NCT07376200 · ClinicalTrials.gov ↗ · Healthy Adult Male
Phase 1 Recruiting 2026-02 China
A Phase I Clinical Trial to Evaluate HECN30227 Injection in Healthy Subjects and Subjects With Chronic Hepatitis B
NCT07771140 · ClinicalTrials.gov ↗ · HBV Infection
Phase 1 Recruiting 2025-12 China
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
NCT04415853 · ClinicalTrials.gov ↗ · Esophageal Cancer
Phase 3 Recruiting 2021-01 China
A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects
NCT07102251 · ClinicalTrials.gov ↗ · Healthy Subjects
Phase 1 Recruiting 2025-09 China
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
NCT05139719 · ClinicalTrials.gov ↗ · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
Phase 2 Recruiting 2023-02 China
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
NCT05133882 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Adult
Phase 1/2 Recruiting 2022-10 China
The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder
NCT04984512 · ClinicalTrials.gov ↗ · Depressive Disorder, Major
Phase 2/3 Recruiting 2021-12 China
HEC169096 in Participants With Advanced Solid Tumors
NCT05451602 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1/2 Recruiting 2022-10 China
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
NCT05586074 · ClinicalTrials.gov ↗ · Leukemia, Acute Myeloid (AML)
Phase 3 Recruiting 2023-03 China
A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects
NCT07099118 · ClinicalTrials.gov ↗ · Non - Alcoholic Steatohepatitis
Phase 1 Recruiting 2025-09 China
HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors
NCT07824934 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors
Phase 1 Not yet open 2026-09 China
A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants
NCT07341672 · ClinicalTrials.gov ↗ · Healthy Adult Subject
Phase 1 Not yet open 2026-12 China
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
NCT05048368 · ClinicalTrials.gov ↗ · Esophageal Cancer, Advanced Solid Tumor
Phase 1 Not yet open 2026-10 China
Phase ll Study of HEC585 in Patients With IPF
NCT05060822 · ClinicalTrials.gov ↗ · Idiopathic Pulmonary Fibrosis
Phase 2 Active, closed 2021-06 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Sunshine Lake Pharma trials

12 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Sunshine Lake Pharma trials

14 conditions
Esophageal Cancer2Advanced Solid Tumor2Idiopathic Pulmonary Fibrosis (IPF)1Healthy Adult Male1HBV Infection1Healthy Subjects1Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)1Acute Myeloid Leukemia, Adult1Advanced Malignant Solid Tumors1Depressive Disorder, Major1Healthy Adult Subject1Idiopathic Pulmonary Fibrosis1Leukemia, Acute Myeloid (AML)1Non - Alcoholic Steatohepatitis1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1511

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Esophageal Cancer

SponsorTrials
Cancer Institute and Hospital, Chinese Academy of Medical Sciences7
Tianjin Medical University Cancer Institute and Hospital6
Zhejiang University5
The First Affiliated Hospital of Zhengzhou University3
Fujian Medical University Union Hospital3
Jazz Pharmaceuticals2
The First Affiliated Hospital of Henan University of Science and Technology2
Perspective Therapeutics1
Energenx Medical1
Tongji University1

Sponsors with the most current trials registered for this condition.

06

Questions about Sunshine Lake Pharma trials

How many clinical trials does Sunshine Lake Pharma sponsor?

Sunshine Lake Pharma is the lead sponsor of 15 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Sunshine Lake Pharma trials recruiting?

Yes. 11 of its 15 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Sunshine Lake Pharma testing?

Its current trials name 12 drugs and biologicals as interventions. The most frequent are Clifutinib (2), HEC585 (2), Pirfenidone (2), Azacitidine (1) and Bevacizumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.